User:SCPdude629/sandbox

A global research and or cause is dedicated and emphasizing on the development and the production of possible candidates and distribution of vaccine doses against the Herpes Simplex Virus. Clinical trials of the early doses began sometime between 2019 and 2020, the onset of the Covid-19 Pandemic. As of 2022, further research and breakthroughs were made but no clinically proven vaccine is yet announced or approved.

As of now, various vaccines are under development and preceding with clinical trials such as the UB-621 which is designed to help produce antibodies against HSV-2, which cause Genital Herpes in Men and Women. Another vaccine candidate example is the "GSK HSV Vaccine" (GSK4108771A) which is designed to amplify antibodies and mRNA for proper and enhanced immune response to the virus.

According to the World Health Organization (WHO), roughly 3.7 billion people worldwide are affected by the virus in some way, a ratio of 1 in 2 people. Whether if it's HSV-1 or HSV-2, ranging from the ages of 15-49 years old.

Transmission
HSV-1 is mainly transmitted by oral to oral contact to cause infection in or around the mouth area while HSV-2 is contracted via genital or sexual contact with those infected. However both can "vice versa" be transferred easily through physical contact in general, although Herpes are however most contagious through fluid bursting from a cold sore if in contact.

Biology/Survival
HSV hides itself with sensory neurons of the nervous system, allowing it to lay dormant and inactive to re-infect the skin at recurring date. The infection is typically and latently lifelong and thus cannot be eradicated from the body.